Hims & Hers can't sell off-brand Ozempic forever, but it can still sell these weight-loss meds
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...
Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
ConsumerAffairs48m
Hims & Hers withdraws from Wegovy, Ozempic market
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Scripps News on MSN6h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Hims Stock Drops on Uncertainty About Weight-Loss Business
Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...
24/7 Wall St3h
HIMS Stock Craters - Is It a Buying Opportunity?
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
24/7 Wall St. on MSN1d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...